A randomised, open label, three periods, three-treatment crossover study to evaluate the pharmacokinetics of alendronic acid oral formulations after single dose administration in healthy volunteers under fasted conditions: a pilot study

2025-522606-20-00 Protocol ALIQ-0225/PKP Human pharmacology (Phase I) - Other Ended

Start 6 Oct 2025 · End 19 Nov 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol ALIQ-0225/PKP

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 24
Countries 1
Sites 1

Pharmacokinetic study in healthy volunteers under fasted conditions.

Key facts

Sponsor
Faes Farma S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
6 Oct 2025 → 19 Nov 2025
Decision date (initial)
2025-09-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Pharmacokinetic study in healthy volunteers under fasted conditions.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Faes Farma S.A.

Sponsor organisation
Faes Farma S.A.
Address
Autonomia Etorbidea 10
City
Leioa
Postcode
48940
Country
Spain

Scientific contact point

Organisation
Faes Farma S.A.
Contact name
FAES FARMA Clinical Department

Public contact point

Organisation
Faes Farma S.A.
Contact name
FAES FARMA Clinical Department

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 24 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
Clinical Unit, Prazska 1486/18c, Hostivar, Prague

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2025-10-06 2025-11-19 2025-10-06 2025-10-23

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-08-07 Czechia Acceptable
2025-09-08
2025-09-08
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-09-12 Czechia Acceptable
2025-09-08
2025-09-12
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-10-08 Czechia Acceptable
2025-09-08
2025-10-08
4 NON SUBSTANTIAL MODIFICATION NSM-3 2025-12-15 Czechia Acceptable
2025-09-08
2025-12-15